On this page
In short: MK-677, or ibutamoren, is an orally active non-peptide agonist at the ghrelin receptor. It raises growth hormone and IGF-1 by amplifying the body's own pulsatile GH release rather than replacing it. Across two decades of trials it consistently produced higher IGF-1, more fat-free mass and increased appetite — and consistently failed to translate that into measurable improvements in strength or physical function.
- It is not a SARM. Ibutamoren has no androgen receptor activity; it acts on GHS-R1a, the ghrelin receptor.
- It is a secretagogue, not a hormone — it prompts the pituitary to release GH, preserving the natural pulse pattern that injected GH overrides.
- The biochemical response is the most reproducible finding: IGF-1 rises and stays elevated for as long as dosing continues, out to two years in the longest trial.
- Lean mass increases; function does not follow. This mass-versus-function gap is the single most consistent theme in the literature.
- Two effects recur in every trial and are mechanistically expected: increased appetite and reduced insulin sensitivity.
What MK-677 is
Ibutamoren is a spiropiperidine-derived small molecule developed at Merck in the 1990s, part of a deliberate search for an orally active alternative to injected growth hormone. It is not a peptide, which distinguishes it sharply from the growth hormone-releasing peptides it is usually shelved beside — Ipamorelin, GHRP-2 and GHRP-6 are amino acid chains; ibutamoren is a synthetic small molecule that happens to hit the same receptor.
It is also, despite its usual retail placement, not a selective androgen receptor modulator. It has no meaningful affinity for the androgen receptor at all. Our guides on SARMs and peptides cover why those categories keep absorbing compounds that do not belong to them.
Mechanism: borrowing ghrelin's signal
Ghrelin is the stomach-derived hormone best known for driving hunger, but its receptor — GHS-R1a, expressed in the hypothalamus and pituitary — also sits upstream of growth hormone release. Ibutamoren binds that receptor and mimics the signal.
The consequence worth understanding is how GH goes up. Injected growth hormone floods the system with a flat, non-physiological concentration and suppresses the body's own production through feedback. Ibutamoren instead increases the amplitude of the pulses the pituitary is already generating, leaving the underlying rhythm intact. In trials this shows up as a higher 24-hour GH profile with pulsatility preserved, and a durable rise in IGF-1 — the liver-derived mediator through which most downstream GH effects are expressed.
Two practical properties follow from being a small molecule rather than a peptide: it survives the gut, so it is orally active where the GHRPs are not, and its effect on the GH axis persists across a full day from a single administration. Both were the point of the original drug discovery programme.
This is a summary of published research findings. It contains no dosing, administration or protocol information, and none of the compounds discussed are approved for human use. Everything below describes what investigators measured in controlled studies.
What the studies measured
Restoring a younger GH profile in older adults
The foundational work came from Chapman and colleagues in the mid-1990s. In healthy older adults, daily oral ibutamoren raised the 24-hour GH profile and brought serum IGF-1 back into the range typical of healthy young adults within weeks. This reframed the compound's premise: not supplementation, but restoration of a signal that declines with age.
The two-year trial — the most important dataset
Nass and colleagues published the definitive study in 2008: a two-year, randomised, placebo-controlled trial in healthy older adults, an unusually long run for a compound of this kind. The biochemical result held — GH and IGF-1 rose to young-adult levels and stayed there for the full duration, with no evidence of tachyphylaxis.
Body composition moved as predicted: roughly a kilogram of fat-free mass gained over placebo, sustained across the two years. Fat mass did not meaningfully fall. And the endpoint that mattered most — physical function and strength — showed no significant improvement. The trial also recorded the signals that have followed ibutamoren ever since: increased appetite, transient oedema and muscle pain, and a modest but real rise in fasting glucose alongside reduced insulin sensitivity.
Protecting lean tissue under caloric restriction
One of the more elegant findings came from Murphy and colleagues, who used a short-term hypocaloric diet in healthy volunteers to induce protein catabolism, then measured nitrogen balance. Ibutamoren attenuated the nitrogen loss. As a demonstration of anti-catabolic activity in a controlled human model, it remains one of the cleaner results in the file — and it is the study most often misrepresented in consumer write-ups, which tend to drop the caloric-restriction context entirely.
Sleep architecture
Because GH secretion is tightly coupled to slow-wave sleep, several small studies examined whether a secretagogue would alter sleep itself. Copinschi and colleagues reported increases in slow-wave and REM sleep during short-term administration. The cohorts were small and the finding has not been extensively replicated, but it is mechanistically coherent rather than incidental.
Bone turnover
Studies tracking bone metabolism found increases in markers of bone turnover — both formation and resorption — consistent with GH axis activation. Changes in actual bone mineral density were slower and more modest, which is unsurprising given how long remodelling takes relative to trial length.
Where it failed
The most instructive result is a negative one. Ibutamoren was taken into a trial in older patients recovering from hip fracture — a population where added lean mass should plausibly translate into faster functional recovery. It did not deliver the functional benefit the mechanism promised, and the compound was not pursued to approval. Read alongside the two-year trial, a consistent picture emerges: ibutamoren reliably changes the biochemistry and modestly changes body composition, but the leap to function has never been demonstrated.
Known in-vivo effects, by strength of evidence
The pips indicate how consistently each effect appears across the published human trials — three for findings reproduced in multiple independent studies, one for findings resting on a single small study.
| Effect | Direction and magnitude | Consistency |
|---|---|---|
| Serum IGF-1 | Increased and sustained; reaches young-adult range in older cohorts | |
| GH pulse amplitude | Increased, with natural pulsatility preserved | |
| Appetite and food intake | Increased — a direct consequence of ghrelin receptor agonism | |
| Fat-free mass | Increased, around a kilogram over two years in older adults | |
| Insulin sensitivity | Reduced; fasting glucose rises modestly | |
| Body weight | Increased, reflecting both lean mass and fluid | |
| Fat mass | Largely unchanged in most trials | |
| Oedema, arthralgia, myalgia | Reported, generally transient — classic GH-axis effects | |
| Nitrogen balance under caloric restriction | Improved; catabolism attenuated | |
| Slow-wave and REM sleep | Increased in short-term studies | |
| Bone turnover markers | Increased; density changes small over trial timeframes | |
| Strength and physical function | No consistent improvement, including in the two-year trial |
What the research does not show
- No approval anywhere. Despite an extensive trial programme, ibutamoren was never approved as a medicine in any jurisdiction.
- Mass is not function. The failure to convert added lean mass into measurable performance is the central unresolved problem, not a footnote.
- The glucose signal is real. Reduced insulin sensitivity appears across trials and is the finding most often omitted from summaries of this compound.
- Long-term data stops at two years, in a specific population — healthy older adults. Nothing published extends beyond that.
- Appetite stimulation cuts both ways. Useful in a cachexia model, a confounder in a body composition study, and an effect no trial has been able to separate from the rest.
Regulatory status
Ibutamoren is not an approved medicine and is supplied strictly as a laboratory reference material. Growth hormone secretagogues are explicitly named under section S2 of the World Anti-Doping Agency's Prohibited List and are banned at all times, in and out of competition. Regulators have issued warnings to companies marketing it as a dietary supplement. Supply for in-vitro and laboratory research, correctly labelled and not marketed for human consumption, is the basis on which reference material is sold — consistent with 21 C.F.R. §§ 312.2(b)(3) and 312.160.
MK-677 is supplied strictly for laboratory and in-vitro research. It is not a medicine, is not for human or veterinary use, and is not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol for administration.
Frequently asked questions
Is MK-677 a SARM?
No. MK-677 is a growth hormone secretagogue acting at the ghrelin receptor, GHS-R1a. It has no androgen receptor activity and is grouped with SARMs only by retail convention.
Is MK-677 a peptide?
No. It is a non-peptide small molecule. That is precisely what distinguishes it from the growth hormone-releasing peptides that target the same receptor — being a small molecule is why it is orally active and long-lasting where they are neither.
What has MK-677 been studied for?
Age-related decline in the growth hormone axis, body composition in older and obese adults, protein catabolism under caloric restriction, recovery after hip fracture, growth hormone deficiency, and sleep architecture.
What does MK-677 reliably demonstrate in vivo?
Sustained increases in growth hormone pulse amplitude and IGF-1, increased fat-free mass, increased appetite and body weight, and reduced insulin sensitivity. What it has not demonstrated is improvement in strength or physical function.
Why was MK-677 never approved?
Because the biochemical and body-composition changes did not translate into functional benefit at the clinical endpoints tested, including recovery from hip fracture — while the metabolic signal on glucose handling remained.
Selected reading
Starting points in the primary literature — each title links to its record on PubMed. These are provided for reference and are not endorsements of any particular finding.
- Chapman IM, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. Journal of Clinical Endocrinology & Metabolism, 1997.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 2008.
- Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism, 1998.
- Copinschi G, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone secretagogue, MK-677, on 24-hour growth hormone profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology & Metabolism, 1996.
- Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 1998.
- Adunsky A, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics, 2011.
- World Anti-Doping Agency. Prohibited List, section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics.
Continue reading
Purity and identity confirmed by third-party analysis, individually lot-tracked, with the full report published before listing.
This article is provided for educational and informational purposes only and is based on published research. Core Labs supplies research chemicals for laboratory use exclusively. Products are not approved for human consumption, nor for medical, veterinary or household use.